Published in Obesity and Diabetes Week, May 8th, 2006
By expanding the trial, Emisphere will be able to evaluate the performance of all three active arms of the trial against each other for statistical significance. Without the additional patients, Emisphere would have been limited to evaluating each of the active arms against only the placebo for statistical significance. Based on the current enrollment rate, the company expects to complete the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.